alsonex.com.au
Alsonex
Alsonex Pty Ltd is Focused On the Development of New Treatments for Neurodegenerative Disease
Alsonex is a biopharmaceutical company focused on the development of new treatments for neurodegenerative disease. The company was founded in 2014 and arose out of research being undertaken at the University of Queensland and elsewhere into neuroinflammation and neurodegenerative disease.
Neurodegenerative disease remains a complex and elusive goal for the pharmaceutical industry, but one in which new research is beginning to shed some light, and for which new treatment options are emerging. Alsonex plans to be part of the solution to slowing or reversing neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and Motor Neuron Disease. A key part of the business model is to advance products through to the proof-of-concept stage in patients. For the longer and more costly clinical studies, development risk will be shared with a larger pharmaceutical or biotechnology company.
Our Principal Commercial Objective
The principal objective of the company is to develop a new treatment option for people with neurodegenerative diseases and this aligns with our commercial objective, which is to enhance shareholder value through clinical development of ALS-205.
- The furthest advanced project is for treating Motor Neuron Disease (MND) or Amyotrophic Lateral Sclerosis (ALS).
- Additional projects involve expanding the clinical utility of the leading molecule into other degenerative diseases of the CNS and benefits from the preclinical work undertaken for the first indication. Additional indications include Alzheimer's Disease and Huntington's Disease.
- Earlier projects are focused on validation of the biochemical target and may lead to additional commercialization opportunities as the studies progress.
- The leading compound, ALS-205, has completed a Single Ascending and Multiple Ascending Dose Phase I clinical trial in healthy volunteers, establishing a suitable dose for future clinical studies.
Our Leadership Team
David Groth, Non-Executive Chairman
David is a co-founder and director of Integra Advisory. David has over 20 years of experience in advising companies and in senior management positions. David has managed a significant number of initial public offers, secondary capital raisings, mergers and acquisition transactions as part of developing and maintaining long term relationships with clients.
David has also held a number of senior management positions (including CEO) providing him with a management and client perspective of capital raisings, M&A transactions, strategic advice and stakeholder/investor relations. Prior to establishing Integra Advisory, David spent 18 years at Wilson HTM. During this time, David held several senior positions, including the Chief Executive Officer.
Alan Robertson, Chief Executive Officer and Managing Director
Alan was the CEO and MD of Pharmaxis Ltd for 14 years. He was responsible for raising more than $350 million in the U.S., Europe and Australia. In that role, he oversaw the development to marketing authorisation a new inhaled dry powder treatment for cystic fibrosis (Bronchitol) and a bronchial challenge test for hyperactive airway disease (Aridol). He also built a drug discovery capability within Pharmaxis and participated in the creation of PXS4728 – now licensed to Boehringer Ingelheim for the treatment of NASH. Previously, he was the CEO of Promics Ltd (now part of Teva) and developed the first C5a receptor antagonist to patients with rheumatoid arthritis. While head of drug discovery at Kinacia, he invented KN-309, a PI3 kinase inhibitor (subsequently licensed to Astra Zeneca). He is a former member of the scientific advisory board of Xenome Limited, a former Non-Executive Director of Patrys Limited and is a current non-executive director of Advent Ltd. While in the UK, as a Senior Scientist at Wellcome PLC, he invented the anti-migraine drug Zomig.
Read More
Trent Woodruff,Scientific Advisor
A/Prof Woodruff is an ARC Future Fellow conducting research into the innate immune system in the brain. Specific research revolves around the Complement System. A focus of his work has been the chronic neurodegenerative diseases amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s disease as well as maintaining an active interest in Alzheimer’s disease. In 2010, A/Prof Woodruff started his own group and independent laboratory at the University of Queensland.
Alan Scott, Non-Executive Director
Alan has experience in corporate reorganisation and M&A. He was the previous Chairman and Managing Director of Progen Industries for 11 years, including listing on the ASX and completing a direct NASDAQ cross listing. More recently, he was the managing director of Promics Pty Ltd and executed a trade sale to Cephalon/Teva. Currently, he is the CEO of Biosecurity/Opti Grow.
Paul Field, Strategic Advisor
Paul has over 25 years of business development experience across a range of disease areas, including CNS disorders, and a deep network in the global biopharmaceutical industry. His current roles include business development manager at BioCurate, which was established in 2017 by Monash University and the University of Melbourne to commercialise drug discoveries in their two institutions. He was previously the life sciences specialist at Austrade, the Australian Government’s investment promotion agency, where he facilitated foreign direct investment into Australian research in infectious diseases, autoimmune diseases, neurodegenerative diseases, cancer and other therapeutic areas. Earlier, Paul was the founder and Executive Chairman of Bio-Link, a privately-owned biotechnology business development company with a range of clients across Australia.
